Infection deteriorating hepatitis B virus related acute-on-chronic liver failure: a retrospective cohort study

Xing-Ran Zhai  
Peking University Health Science Centre

Jing-Jing Tong  
5th Medical Center of Chinese PLA General Hospital

Hong-Min Wang  
Peking University Health Science Centre

Xiang Xu  
5th Medical Center of Chinese PLA General Hospital

Xiu-Ying Mu  
Peking University Health Science Centre

Jing Chen  
5th Medical Center of Chinese PLA General Hospital

Zi-Feng Liu  
Medical School of Chinese PLA

Yu Wang  
Medical School of Chinese PLA

Hai-Bin Su  
5th Medical Center of Chinese PLA General Hospital

Jin-Hua Hu  
5th Medical Center of Chinese PLA General Hospital

Research article

Keywords: Acute-on-chronic liver failure, Hepatitis B virus, Infections, Prognosis

DOI: https://doi.org/10.21203/rs.3.rs-38665/v1

License: © This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

Background: Infection is common in acute-on-chronic liver failure (ACLF), which may worsen the clinical condition and prognosis. However, the characteristics of infection and its influence on prognosis in hepatitis B virus related ACLF (HBV-ACLF) as defined by the European Association for the Study of the Liver (EASL) have not been clarified. We aimed to investigate the characteristics of infection and its influence on mortality in HBV-ACLF defined by EASL in China.

Methods: We performed a retrospective cohort study with HBV-ACLF patients defined by EASL in a single center from January 2015 to December 2017. Patients were divided into an infection group and a non-infection group. The incidence, sites, strains of infection, and risk factors for mortality were evaluated.

Results: A total of 289 patients were included, of which 185 (64.0%) were diagnosed with an infection. The most common was pneumonia (55.7%), followed by spontaneous bacterial peritonitis (47.6%) and others. The gram-negative bacteria were the most frequent (58.3%). Patients with one, two, and three or more infection sites had a gradually increasing incidence of sepsis (P<0.01), sepsis shock (P<0.001), and ACLF-3 (P<0.05). One, two, and three or more strains were isolated in 86, 16, and 18 patients, who showed a growing incidence of sepsis (P<0.01) and sepsis shock (P<0.001). Infection was identified as an independent risk factor for 28-day mortality in HBV-ACLF patients. Infected patients showed a significantly higher 28-day mortality than those without (P<0.01), especially in patients with ACLF-3. Pneumonia and sepsis were identified as independent predictors of 28-day mortality for infected patients.

Conclusions: Infection is associated with severe clinical course and high mortality in HBV-ACLF defined by EASL. The increased incidence of sepsis and sepsis shock was associated with an increased number of infection sites and isolated strains. Pneumonia and sepsis were independent predictors affecting mortality in HBV-ACLF patients with infection.

Background

The definition and diagnostic criteria of acute-on-chronic liver failure (ACLF) are different in eastern and Western countries. Based on the European Association for the Study of the Liver (EASL), ACLF was defined as a severe clinical syndrome characterized by acute liver injuries, organ failures (OFs), and high short-term mortality in patients with liver cirrhosis due to multiple etiologies[1]. In western countries, alcoholic liver disease is the most common cause of ACLF. However, in the east of Asia, the hepatitis B virus (HBV) infection accounts for the overwhelming majority of etiology[2]. Patients with HBV-related ACLF (HBV-ACLF) are susceptible to infectious complications due to impaired immune function, intestinal barrier dysfunction, and genetic predisposition[3]. Previous studies reported that infection resulted in the progression of ACLF as defined by EASL and even led to higher clinical severity scores and short-term mortality[4-6], possibly due to the production and release of inflammatory cytokines that lead to hepatocyte necrosis and apoptosis[7]. However, the etiology of these patients is complex and high alcohol consumption accounts for the majority. As demonstrated in a study[8], the characteristics of HBV-ACLF were markedly distinct from those of alcohol-related ACLF, manifesting higher clinical severity, mortality risk, higher incidence of liver failure, lower incidence of kidney failure and trigger events. Thus, the influence of infection on the prognosis of patients with HBV-ACLF as defined by EASL is still poorly understood to date, waiting to be stated.

The objective of this study is to demonstrate the detailed features of infection in HBV-ACLF patients defined by EASL and explore its influence on the clinical condition and 28-day mortality.

Methods

Ethical approval

This study accords with the ethical guidelines of the 1975 Declaration of Helsinki and was approved by the Ethical Committee of the Fifth Medical Center of Chinese PLA General Hospital (No. 2019016D). Informed consent was waived due to the study was retrospectively designed and the data were anonymous.

Patient selection

This cohort study consecutively retrospectively included 345 patients with HBV-ACLF hospitalized from January 2015 to December 2017 in the Fifth Medical Center of Chinese PLA General Hospital. Chronic hepatitis B was diagnosed by hepatitis B surface antigen and/or hepatitis B virus deoxyribonucleic acid (HBV-DNA) positivity for ≥6 months[9]. ACLF was diagnosed based on the criteria proposed by the EASL/the American Association for the Study of Liver Diseases[10-12]. The exclusion criteria were as follows: (1) Less than 18 years old; (2) Hepatocellular carcinoma or other malignant tumors; (3) Serious extra-hepatic diseases; (4) Received liver transplantation within 28 days; (5) Lost to follow-up within 28 days; (6) Hospital stay less than 48 hours; (7) Pregnancy.

Definitions related to infection
The diagnostic criteria for bacterial infection were listed as follows. (1) Spontaneous bacterial peritonitis (SBP): neutrophils count $\geq 250$/mm$^3$ in ascitic fluid. (2) Pneumonia: clinical manifestations of infection associated with imaging examination showing that new pulmonary infiltration. (3) Urinary tract infection (UTI): high white blood cell (WBC) count ($>10$/field) was found in urinary sediment accompanied by positive culture results of urine or innumerable WBC per field with negative culture results of urine. (4) Bacteremia: positive blood culture. (5) Skin and soft tissue infection (SSTI): symptoms of infection, such as redness, infection, high temperature, and pain on the skin. (6) Spontaneous bacterial empyema (SBE): neutrophils number in pleural fluid $\geq 250$/mm$^3$. (7) Infectious diarrhea: diarrhea with stool microscopic examination showing WBC or routine stool culture showing evidence of pathogenic microorganisms. (8) Cholangitis: right upper abdominal pain, cholestasis, or radiologic evidence of biliary obstruction. (9) Unproven infection: the existence of febrility and leukocytosis need antibiotic treatment with no recognizable sources$^{[13-18]}$.

The criteria used to define fungal infection were as follows. (1) Invasive candidiasis: detection of Candida spp in the cultures of blood or from other normally aseptic body fluids. (2) Invasive aspergillosis: discovery of Aspergillus by direct laboratory inspection or culture of respiratory specimens when the radiological evidence was consistent with lung infection$^{[16]}$.

Bacteria/fungal infection was grouped as community-acquired (CA), healthcare-associated (HCA), and nosocomial (NS) infections. NS infection referred to an infection that occurred 48 hours after hospitalization. HCA infection was defined as an infection that occurred within 48 hours after hospitalization and met any of the following: (1) Hospitalization or hemodialysis clinic, or intravenous chemotherapy during the past one month; (2) Hospital stay for $\geq 2$ days, or surgery in the past half a year; (3) Residence in a medical center or a long-term care facility. CA infection referred to an infection that occurred within 48 hours after hospitalization and the patients did not satisfy any criteria for HCA infection$^{[17]}$.

Sepsis and sepsis shock was defined according to Sepsis-3$^{[18]}$. Sepsis can be identified by an increase of the Sequential Organ Failure Assessment (SOFA) score $\geq 2$ points which caused by a maladjusted host response to infection. Sepsis shock requires vasopressor to keep mean arterial pressure (MAP) of 65mmHg or higher and serum lactate level higher than 2 mmol/L in defect of hypovolemia$^{[18]}$.

**Clinical severity scores and HBV-ACLF grade**

The formula for the Model for End-Stage Liver Disease (MELD) score was as follows: $\text{MELD score} = 3.78 \times \ln \left[ \text{Total bilirubin (mg/dL)} \right] + 11.2 \times \ln \left[ \text{INR} \right] + 9.57 \times \ln \left[ \text{Creatinine (mg/dL)} \right] + 6.43$.$^{[18]}$ The formula for MELDNa was as follows: $\text{MELDNa} = \text{MELD} - \text{Na} + 0.025 \times \text{MELD} \times (140 - \text{Na}) + 140$.$^{[20]}$ Child-Turcotte-Pugh (CTP) score was the summation of fractions of the five indexes, including hepatic encephalopathy (HE), ascites, Total bilirubin (TBil), Albumin (Alb), and Prothrombin time prolongation, with 1-3 points for each index, a minimum score of 5, and a maximum score of 15.$^{[21]}$ The OFs were evaluated based on the CLIF-OF score system, and CLIF-C ACLF score was computed as follow: $\text{CLIF-C ACLF} = 10 \times [0.33 \times \text{CLIF-OFs} + 0.04 \times \text{Age} + 0.63 \times \ln \left( \text{WBC count} \right)] - 2$.$^{[22]}$ The SOFA score was assessed as described.$^{[23]}$

ACLF was graded as per the CANONIC study.$^{[16]}$ ACLF grade-1 (ACLF-1) refers to the existence of single kidney failure, or brain failure accompanied by kidney dysfunction or another single OF accompanied by kidney/brain dysfunction; ACLF grade-2 (ACLF-2) refers to the existence of two OFs; ACLF grade-3 (ACLF-3) refers to the existence of three or more OFs.

**Statistical analysis**

The data were analyzed using SPSS software (version 24.0, IBM Corporation, Armonk, NY, USA) and plotted using the GraphPad Prism software (version 7.00, GraphPad Software, Inc., La Jolla, CA, USA) and Medcalc software (version 15.2.2, Medcalc Software baba, Ostend, Belgium). Measurement data with normal distribution were expressed as mean $\pm$ standard deviation (SD), and the t-test was used for comparison between two groups or analysis of variance for comparison among three or more groups. Measurement data that did not conform to the normal distribution were represented by the median and interquartile range, and the Kolmogorov-Smirnov Z rank-sum test was used for comparison between two groups or Kruskal-Wallis Test for comparison among three or more groups. Enumeration data were expressed as number (%) and intergroup comparison was performed by the chi-square test. Cox proportional hazards regression model was used for univariate and multivariate analysis of 28-day prognostic independent risk factors. Survival curves were estimated by the Kaplan-Meier method and the comparison was performed with the log-rank test. The difference was considered statistically significant if $P < 0.05$.

**Results**

**Baseline characteristics of patients**

A total of 289 patients with HBV-ACLF were included in this study after excluding 56 patients according to the inclusion and exclusion criteria (Figure 1), among which 236 (81.7%) were males and 53 (18.3%) were females. The mean age was 48 $\pm$ 11 years, range from 22 to 76 years old. A total of 185 (64.0%) patients developed bacterial or fungal infections during the study. Characteristics of HBV-ACLF patients with and without infection are shown in Table 1. Higher WBC count, serum creatinine (sCr), procalcitonin (PCT), lower MAP, Alb, higher incidence of hemorrhage, acute kidney injury (AKI), HE, kidney failure, brain failure, respiratory failure, circulation failure, systemic inflammatory reaction syndrome (SIRS), and higher clinical severity scores including CLIF-C ACLFs, CLIF-C OFs, SOFA scores were presented in patients with infection than patients without.

**Characteristics of infection**
The most common type of infection was pneumonia (55.7%, 103/185), followed by SBP (47.6%, 88/185), bacteremia (20.0%, 37/185), UTI (11.4%, 21/185), SBE (7.0%, 13/185), and other infections. The most common site of acquisition was NS infection in 94 (50.8%) patients, followed by HCA infection in 76 (41.1%), and CA infection in 15 (8.1%).

Positive culture results were detected in 120 among 185 patients with infection, of which gram-positive bacteria, gram-negative bacteria, and fungi were identified in 42 (35.0%), 70 (58.3%), and 44 (36.7%) patients, respectively. Patients infected with fungi showed the highest 28-day mortality of 72.7% compared with 59.5% and 64.3% in those infected with gram-positive and gram-negative bacteria.

210 isolates were acquired from 120 patients with positive culture results. The most frequent isolated pathogen was gram-negative bacteria in 104 specimens (49.5%), among which the most common was Escherichia coli (18.6%), the most common source was ascites, followed by Klebsiella pneumoniae (11.4%), the most common source was ascites, and then Acinetobacter baumannii (5.7%), the most common source was sputum. Gram-positive bacteria were found in 53 (25.2%) isolates, among which the most frequent strain was Enterococcus faecium (9.0%), the most frequent source was ascites, followed by Staphylococcus aureus (3.3%), the most frequent source was sputum, and then Staphylococcus epidermidis (2.9%), the most frequent source was blood. Fungi were isolated in 53 (25.2%) specimens, among which Aspergillus fumigatus (11.0%) was the most prevalent, followed by Candida albicans (8.6%), the most prevalent source of both was sputum (Table 3).

To study the characteristics of infection-related indicators of different infection sites and pathogens, we also analyzed WBC count, percentage of neutrophils, C-reactive protein (CRP), PCT, the incidence of SIRS, sepsis, sepsis shock, and different ACLF grades of single-site infection and single-class pathogen infection. However, there was no statistically significant difference among them (Table 2).

The influence of the increasing number of infection sites and strains on sepsis and sepsis shock

Among the 185 HBV-ACLF patients with infection, 115 (62.2%) presented one infection site, 50 (27.0%) had two, and 20 (10.8%) had three or more. Patients with one, two and three or more infection sites had a gradually increasing incidence of sepsis (57.4% vs 78.0% vs 85.0%, P<0.01), sepsis shock (27.0% vs 48.0% vs 70.0%, P<0.001), ACLF-3 (22.6% vs 20.0% vs 35.0%, P<0.05) and 28-day mortality (59.1% vs 64.0% vs and 85.0%, P>0.05) (Table 2).

One, two, and three or more strains were isolated in 86 (71.7%), 16 (13.3%), and 18 (15.0%) patients, respectively, who showed a gradually increasing incidence of sepsis (57.0% vs 75.0% vs 100.0%, P<0.01), sepsis shock (24.4% vs 56.3% vs 94.4%, P<0.001), and 28-day mortality (60.5% vs 62.5% vs 77.8%, P<0.05) (Table 2).

The influence of infection on 28-day mortality in HBV-ACLF patients

Patients with infection showed higher 28-day mortality than those without (63.2% vs 44.2%, P<0.01) (Figure 2A). On univariate Cox analysis, the presence of infection, AKI, hemorrhage, HE, high WBC count, TBil, international normalized ratio (INR), creatinine, low serum sodium were associated with 28-day mortality. As creatinine and AKI had a strong correlation, creatinine was excluded in the multivariate Cox analysis. Multivariate Cox regression analysis found that the presence of infection (HR=1.515, 95% CI 1.071-2.144, P<0.05) was an independent risk factor for 28-day mortality. Other independent risk factors for 28-day mortality included the presence of AKI (HR=1.875, 95% CI 1.365-2.577, P<0.001), HE (HR=1.854, 95% CI 1.352-2.544, P<0.001), high TBil (HR=1.001, 95% CI 1.000-1.002, P<0.05), and INR (HR=1.730, 95% CI 1.472-2.035, P<0.001) (Table 4).

Infected patients with ACLF-1, ACLF-2, and ACLF-3 showed a lower 28-day survival rate than those without infection (P<0.0001) (Figure 2B). Among HBV-ACLF grade-3 patients, those with infection showed a significantly higher 28-day mortality than those without (93.0% vs 42.9%, P<0.01). Patients with grade-1 and -2 showed the same tendency as grade-3 although there was no significant difference between infection and no infection group (grade-1: 45.2% vs 41.7%, P=0.737; grade-2: 61.3% vs 45.9%, P=0.070) (Figure 2C).

The influence of pneumonia and sepsis on 28-day mortality in HBV-ACLF patients with infection

Table 5 shows the predictors associated with 28-day mortality in the Cox regression analysis in 185 HBV-ACLF patients with infection. On univariate analysis, the presence of pneumonia, SBP, ascites, AKI, HE, SIRS, sepsis, sepsis shock, elevated WBC, INR were significantly associated with 28-day mortality. As sepsis and sepsis shock had a strong correlation, sepsis shock was excluded in the multivariate Cox analysis. In multivariable Cox regression analysis, the presence of pneumonia (HR=1.904, 95% CI 1.268-2.860, P<0.01) and sepsis (HR=2.166, 95% CI 1.372-3.421, P<0.01) were identified as independent predictors for 28-day mortality. Other independent predictors included the presence of AKI (HR=1.529, 95% CI 1.046-2.235, P<0.05), HE (HR=1.263, 95% CI 1.087-1.466, P<0.01), and elevated INR (HR=1.482, 95% CI 1.229-1.788, P<0.001).

Discussion

Our research is unique because it assessed the characteristics and influence of infection on the clinical condition and short-term prognosis in patients with HBV-ACLF defined by EASL in China. There are four main findings in our research. The first is that pneumonia is the most common form of infection for patients with HBV-ACLF. Gram-negative bacteria were the most frequent cultured microorganisms and were mostly Escherichia coli. Secondly, infectious complications had a negative influence on the short-term prognosis for HBV-ACLF patients. Thirdly, the increased incidence of sepsis and sepsis shock was significantly associated with an increased number of infection sites and isolated strains. Last but not the least,
infection-related indicators including the occurrence of pneumonia and sepsis can serve as independent predictors for short-term mortality in HBV-ACLF patients with infection.

In our research, the most common type of infection was pneumonia, followed by SBP, bacteremia, UTI, SBE, which is basically consistent with the findings of other research\cite{25,29}. Among the 185 patients with infection, 120 had a positive culture result, from whom 210 isolates were acquired. Gram-negative bacteria accounted for the majority of all detected samples and were mostly Escherichia coli isolated from ascites, which was basically in agreement with previous studies\cite{15,24}, possibly owing to bacterial translocation caused by gut dysbiosis and increased permeability\cite{2,25}. Thus, early detection and prompt empirical antibiotic treatment are necessary for the management of HBV-ACLF patients with infection.

In our study, HBV-ACLF patients presented an overall 28-day mortality rate of 56.4%, with a 28-day mortality of 63.2% and 44.2% in patients with infection and those without, respectively. Infection was identified as an independent risk factor for 28-day survival in patients with HBV-ACLF. This negative impact was especially evident in patients with HBV-ACLF grade-3, in whom the 28-day mortality of patients with infection was significantly higher than those without. This result was different from that of a study conducted by Fernández et al\cite{4}, possibly due to different etiologies that caused ACLF or different regions.

Sepsis refers to the development of organ dysfunction caused by infection, which was of predictive value to the prognosis of patients with liver cirrhosis in a recent study\cite{26}. Sepsis shock represents severe circulatory disorders. In our study, increased infection sites and isolated strains were accompanied by an increased incidence of sepsis and sepsis shock, which undoubtedly complicated the clinical condition and make antimicrobial treatment more challenging. This phenomenon has little been found in previous studies. Therefore, more attention should be paid to multiple infections for clinical physicians to avoid the progression of infections.

Previous research\cite{27} reported that pneumonia and sepsis were independent predictors for 30-day mortality in cirrhosis patients with ascites. Our study found that pneumonia and sepsis were identified as independent predictors for 28-day mortality in HBV-ACLF patients with infection. According to the related literature, tracheal intubations\cite{28} and blood products transfusions\cite{29} are considered to be risk factors for pneumonia. Thus, it is imperative to carefully monitor the signs of pneumonia and avoid the related risk factors for early prevention and timely treatment.

Additionally, it has been reported that ACLF patients with fungal infection had a high risk of death\cite{30,31}. Our study also found that fungal infections had a higher mortality rate than bacterial infections. Besides pneumonia and sepsis, we also found that AKI, HE, and INR were independent predictors for 28-day mortality in HBV-ACLF patients with infection. Multiple studies\cite{32,33} have shown that AKI is a risk factor for short-term death in ACLF patients, which is consistent with the results of our study. HE, one of the most common severe complications of ACLF, may cause brain edema and intracranial hypertension, which contribute to the progression of ACLF. INR reflects liver coagulation function and severity of liver necrosis.

Our study had two main limitations. Firstly, the history of invasive manipulation and the use of glucocorticoids before infection were not clear in our database, which may be important to the occurrence of infection. Secondly, this study was retrospectively designed, and it only involved a single center with a relatively limited sample, thus a prospective, multi-center study with a larger sample size on HBV-ACLF patients is necessary to further confirm the results of our study.

Conclusions

Pneumonia is the most common type of infection in HBV-ACLF patients. Gram-negative bacteria accounted for the majority of cultured microorganisms, especially Escherichia coli. Infection was associated with increased mortality in HBV-ACLF patients. The increased incidence of sepsis and sepsis shock was significantly associated with an increased number of infection sites and cultured strains. Pneumonia and sepsis were independent predictors for short-term mortality in HBV-ACLF patients with infection. Clinical physicians should pay more attention to infections, especially pneumonia, sepsis, and multiple infections to avoid the progression of HBV-ACLF.

Abbreviations

ACLF: acute-on-chronic Liver failure; HBV: hepatitis B virus; HBV-ACLF: HBV-related ACLF; HBV-DNA: hepatitis B virus deoxyribonucleic acid; SBP: spontaneous bacterial peritonitis; UTI: urinary tract infection; WBC: white blood cell; SSTI: skin and soft tissue infection; SBE: spontaneous bacterial empyema; CA: community-acquired; HCA: healthcare-associated; NS: nosocomial; SOFA: Sequential Organ Failure Assessment; MAP: mean arterial pressure; MELD: Model for End-Stage Liver Disease; CTP: Child-Turcotte-Pugh; HE: hepatic encephalopathy; TBil: total bilirubin; Alb: albumin; OFs: organ failures; CLIF-C OFs: chronic liver failure consortium organ failure score; CLIF-C ACLFs: chronic liver failure consortium acute-on-chronic liver failure score; SD: standard deviation; sCr: serum creatinine; PCT: procalcitonin; AKI: acute kidney injury; SIRS: systemic inflammatory reaction syndrome; CRP: C-reactive protein; INR: international normalized ratio

Declarations

Ethics approval and consent to participate
This study accords with the ethical guidelines of the 1975 Declaration of Helsinki and was approved by the Ethical Committee of the Fifth Medical Center of Chinese PLA General Hospital (No. 2019016D). Informed consent was waived due to the study was retrospectively designed and the data were anonymous.

**Consent for publication**

Not applicable.

**Availability of data and materials**

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

**Competing Interests**

The authors declare that they have no competing interests.

**Funding**

No funding.

**Authors’ contributions**

ZXR, HJH, and SHB designed this study. ZXR, TJJ, WHM, XX, MXY, CJ, LZF, and WY participated in data collection and analysis. ZXR wrote the first draft with assistance from TJJ, SHB, and HJH. SHB and HJH edited the final draft. All authors read and approved the final manuscript.

**Acknowledgments**

Not applicable.

**References**

[1] Hernaez R, Sola E, Moreau R, Gines P. Acute-on-chronic liver failure: an update[J]. Gut, 2017, 66(3): 541-553.

[2] Gu WY, Xu BY, Zheng X, Chen J, Wang XB, Huang Y, et al. Acute-On-Chronic Liver Failure in China: Rationale for Developing a Patient Registry and Baseline Characteristics[J]. Am J Epidemiol, 2018, 187(9): 1829-1839.

[3] Ekpanyapong S, Reddy KR. Infections in Cirrhosis[J]. Curr Treat Options Gastroenterol, 2019, 17(2): 254-270.

[4] Fernandez J, Acevedo J, Wiest R, Gustot T, Amoros A, Deulofeu C, et al. Bacterial and fungal infections in acute-on-chronic liver failure: prevalence, characteristics and impact on prognosis[J]. Gut, 2018, 67(10): 1870-1880.

[5] Shalimar, Rout G, Jadaun SS, Ranjan G, Kedia S, Gunjan D, et al. Prevalence, predictors and impact of bacterial infection in acute on chronic liver failure patients[J]. Dig Liver Dis, 2018, 50(11): 1225-1231.

[6] Karvellas CJ, Pink F, McPhail M, Austin M, Auzinger G, Bernal W, et al. Bacteremia, acute physiology and chronic health evaluation II and modified end stage liver disease are independent predictors of mortality in critically ill nontransplanted patients with acute on chronic liver failure[J]. Crit Care Med, 2010, 38(1): 121-126.

[7] Bernal W, Auzinger G, Dhawan A, Wendon J. Acute liver failure[J]. Lancet, 2010, 376(9736): 190-201.

[8] Wu T, Li J, Shao L, Xin J, Jiang L, Zhou Q, et al. Development of diagnostic criteria and a prognostic score for hepatitis B virus-related acute-on-chronic liver failure[J]. Gut, 2018, 67(12): 2181-2191.

[9] Hou J, Wang G, Wang F, Cheng J, Ren H, Zhuang H, et al. Guideline of Prevention and Treatment for Chronic Hepatitis B (2015 Update)[J]. J Clin Transl Hepatol, 2017, 5(4): 297-318.

[10] Moreau R, Jalan R, Gines P, Pavesi M, Angeli P, Cordoba J, et al. Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis[J]. Gastroenterology, 2013, 144(7): 1426-1437.

[11] EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis[J]. J Hepatol, 2018, 69(2): 406-460.

[12] Bajaj JS, O’Leary JG, Reddy KR, Wong F, Biggins SW, Patton H, et al. Survival in infection-related acute-on-chronic liver failure is defined by extrahepatic organ failures[J]. Hepatology, 2014, 60(1): 250-256.
Fernandez J, Acevedo J, Prado M, Castro M, Pavesi M, et al. Clinical course and short-term mortality of cirrhotic patients with infections other than spontaneous bacterial peritonitis. Liver Int, 2017, 37(3): 385-395.

Cai J, Zhang M, Han T, Jiang HQ. Characteristics of infection and its impact on short-term outcome in patients with acute-on-chronic liver failure. Medicine (Baltimore), 2017, 96(37): e8057.

Wang C, Ma DQ, Luo S, Wang CM, Ding DP, Tian YY, et al. Incidence of infectious complications is associated with a high mortality in patients with hepatitis B virus-related acute-on-chronic liver failure. World J Clin Cases, 2019, 7(16): 2204-2216.

De Pauw B, Walsh TJ, Donnelly JP, Stevens DA, Edwards JE, Calandra T, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis, 2008, 46(12): 1813-1821.

Merli M, Lucidi C, Giannelli V, Giusto M, Riggio O, Falcone M, et al. Cirrhotic patients are at risk for health care-associated bacterial infections. Clin Gastroenterol Hepatol, 2010, 8(11): 979-985.

Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Ranieri VM, Annane D, Bauer M, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA, 2016, 315(8): 801-810.

Kamath PS, Kim WR. The model for end-stage liver disease (MELD). Hepatology, 2007, 45(3): 797-805.

Pianetti S, Bartoletti M, Tonon M, Baldassarre M, Chies G, Romano A, et al. Assessment of Sepsis-3 criteria and quick SOFA in patients with cirrhosis and bacterial infections. Gut, 2018, 67(10): 1892-1899.

Hung TH, Tseng CW, Hsieh YH, Tseng KC, Tsai CC, Tsai CC. High mortality of pneumonia in cirrhotic patients with ascites. BMC Gastroenterol, 2013, 13: 25.

Uvizl R, Kolar M, Herkel T, Vobrova M, Langova K. Possibilities for modifying risk factors for the development of hospital-acquired pneumonia in intensive care patients: results of a retrospective, observational study. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub, 2017, 161(3): 303-309.

Benson AB, Burton JR Jr., Austin GL, Biggins SW, Zimmerman MA, Kam I, et al. Differential effects of plasma and red blood cell transfusions on acute lung injury and infection risk following liver transplantation. Liver Transpl, 2011, 17(2): 149-158.

Zhang H, Liu F, Liu H, You S, Zhu B, Wan Z, et al. Incidence, risk factors and outcomes of acute kidney injury (AKI) in patients with acute-on-chronic liver failure (ACLF) of underlying cirrhosis. Hepatol Int, 2016, 10(5): 807-818.

Chen N, Chen X, Ding X, Teng J. Analysis of the high incidence of acute kidney injury associated with acute-on-chronic liver failure. Hepatol Int, 2018, 12(3): 262-268.
Tables
## Table 1 Baseline characteristics of HBV-ACLF patients with and without infection

| Variables                      | Infection (n=185) | No infection (n=104) | P value |
|--------------------------------|-------------------|----------------------|---------|
| **Age (years)**                | 48±11             | 48±11                | 0.731   |
| **Male (%)**                   | 151(81.6)         | 85(81.7)             | 0.982   |
| **BMI (kg/m²)**                | 24.9(22.4,27.7)   | 25.0(22.1,28.1)      | 0.990   |
| **MAP (mmHg)**                 | 85(79,95)         | 89(81,96)            | 0.028   |
| **HBV-DNA level (IU/ml)**      | 0.427             |                      |         |
| ≤200                           | 41(22.3)          | 20(19.2)             | 0.543   |
| 200-2×10⁴                      | 42(22.8)          | 33(31.7)             | 0.098   |
| 2×10⁴-2×10⁶                    | 57(31.0)          | 28(26.9)             | 0.469   |
| ≥2×10⁶                         | 44(23.9)          | 23(22.1)             | 0.729   |
| **Laboratory data**            |                   |                      |         |
| **WBC count (10⁹/L)**          | 9.7(6.5,13.1)     | 7.4(5.5,9.3)         | <0.001  |
| **Platelet count (10⁹/L)**     | 64(40,102)        | 71(45,108)           | 0.201   |
| **Total bilirubin(μmol/L)**    | 339±162           | 366±155              | 0.164   |
| **Albumin (g/L)**              | 28.0(24.0,30.5)   | 29.0(26.3,32.0)      | 0.008   |
| **ALT (U/L)**                  | 102(42,243)       | 96(43,199)           | 0.881   |
| **AST (U/L)**                  | 135(79,278)       | 128(84,249)          | 0.855   |
| **ALP (U/L)**                  | 124(100,169)      | 142(110,171)         | 0.189   |
| **GGT (U/L)**                  | 50(33,78)         | 49(34,74)            | 0.736   |
| **INR**                        | 2.4(1.9,2.8)      | 2.5(2.0,2.7)         | 0.214   |
| **Creatinine (μmol/L)**        | 135(90,193)       | 111(82,147)          | 0.015   |
| **Serum sodium(mmol/L)**       | 133(129,137)      | 133(128,137)         | 0.997   |
| **HBeAg (%)**                  | 97(53.0)          | 50(48.1)             | 0.422   |
| **CRP (mg/L)**                 | 17.8(9.1,53.9)    | 12.8(8.4,20.8)       | 0.050   |
| **Procalcitonin(ng/ml)**       | 1.2(0.5,3.2)      | 0.6(0.4,1.1)         | <0.001  |
| **Complications (%)**          |                   |                      |         |
| **Ascites**                    | 171(92.4)         | 94(90.4)             | 0.545   |
| **Hemorrhage**                 | 25(13.5)          | 6(5.8)               | 0.041   |
| **Acute kidney injury**        | 107(57.8)         | 43(41.3)             | 0.007   |
| **HE**                         | 93(50.3)          | 65(62.5)             | 0.036   |
| **Organ failure (%)**          |                   |                      |         |
| **Liver failure**              | 154(83.2)         | 93(89.4)             | 0.153   |
| **Coagulation failure**        | 87(47.0)          | 60(57.7)             | 0.090   |
| **Kidney failure**             | 54(29.2)          | 17(16.3)             | 0.015   |
| **Cerebral failure**           | 33(17.8)          | 6(5.8)               | 0.004   |
| **Respiratory failure**        | 24(13.0)          | 3(2.9)               | 0.005   |
| **Circulation failure**        | 22(11.9)          | 1(1.0)               | 0.001   |
| **Prognostic score**           |                   |                      |         |
| **CLIF-C ACLFs**               | 48(44,53)         | 44(40,48)            | <0.001  |
| **CLIF-C OFs**                 | 10(10,12)         | 10(9,11)             | 0.002   |
| **MELD**                       | 30(26,34)         | 29(25,32)            | 0.099   |
| **MELDNa**                     | 31(28,36)         | 31(27,34)            | 0.065   |
|                  | CTP         | SOFA        | ACLF grade (%) | SIRS (%) |
|------------------|-------------|-------------|----------------|----------|
|                  | 13(12,13)   | 12(11,13)   | 0.066          |          |
| SOFA             | 9(8,11)     | 8(6,9)      | <0.001         |          |
| ACLF grade (%)   |             |             |                |          |
| ACLF-1           | 62(33.5)    | 36(34.6)    | 0.849          |          |
| ACLF-2           | 80(43.2)    | 61(58.7)    | 0.012          |          |
| ACLF-3           | 43(23.2)    | 7(6.7)      | <0.001         |          |
| SIRS (%)         | 57(30.8)    | 12(11.5)    | <0.001         |          |

Abbreviations: HBV-ACLF: hepatitis B virus related acute-on-chronic liver failure; BMI: body mass index; MAP: mean arterial pressure; HBV-DNA: hepatitis B virus deoxyribonucleic acid; WBC: white blood cells; ALT: alanine aminotransferase; AST: aspartate aminotransferase; ALP: alkaline phosphatase; GGT: gamma-glutamyl transpeptidase; INR: international normalized ratio; HBeAg: hepatitis B virus envelope antigen; CRP: C-reactive protein; HE: hepatic encephalopathy; CLIF-C ACLFs: chronic liver failure consortium acute-on-chronic liver failure score; CLIF-C OFs: chronic liver failure consortium organ failure score; MELD: model for end stage liver disease; CTP: Child-Turcotte-Pugh; SOFA: sequential organ failure assessment; SIRS: system inflammatory reaction syndrome.
Table 2 Characteristics of infection-related indicators of different infection sites and pathogens

| Variables         | N   | WBC count (10^9/L) | N(%) | CRP(mg/L) | PCT(ng/ml) | SIRS(%) | Sepsis(%) | Sepsis shock(%) | ACLF-1(%) | ACLF-2(%) | ACLF-3(%) |
|-------------------|-----|--------------------|------|-----------|------------|---------|-----------|-----------------|-----------|-----------|-----------|
| **Type of infections** |     |                     |      |           |            |         |           |                 |           |           |           |
| Pneumonia alone   | 52  | 10.3(7.3,13.6)     | 82(72.89) | 16.4(11.0, 4.7) | 1.4(0.8,4.4) | 16(30.8)| 33(63.5) | 19(36.5) | 10(19.2): | 25(48.1): | 17(32.7): |
| SBP alone         | 37  | 9.1(5.8,13.1)      | 79(67.85) | 17.5(8.8,51.2) | 1.0(0.5,1.6) | 14(37.8)| 17(45.9) | 6(16.2)  | 12(32.4): | 20(54.1): | 5(13.5)  |
| Bacteremia alone  | 10  | 11.1(6.6,15.5)     | 71(65.82) | 41.0(24.5,5.9) | 2.2(1.0,4.6) | 3(30.0)| 6(60.0)  | 2(20.0)  | 4(40.0):  | 4(40.0):  | 2(20.0): |
| Others*           | 16  | 8.7(4.8,14.9)      | 73(62.82) | 26.4(9.4,68.6) | 1.1(0.5,5.0) | 5(31.3)| 10(62.5) | 4(25.0)  | 5(31.3):  | 9(56.3):  | 2(12.5): |
| **Number of infection sites** |     |                     |      |           |            |         |           |                 |           |           |           |
| One               | 115 | 9.9(6.5,13.5)      | 79(68.86) | 18.9(11.2,3.0) | 1.4(0.5,2.8) | 38(33.0)| 66(57.4)** | 31(27.0)** | 31(27.0): | 58(50.4): | 26(22.6)* |
| Two               | 50  | 9.2(5.1,13.7)      | 81(74.87) | 19.0(10.9,6.9) | 1.5(0.6,4.1) | 17(34.0)| 39(78.0) | 24(48.0) | 22(44.0): | 18(36.0): | 0(20.0): |
| Three or more     | 20  | 12.9(6.9,21.8)     | 81(76.84) | 55.6(10.1,9.5) | 0.9(0.7,4.9) | 8(40.0)| 17(85.0) | 14(70.0) | 9(45.0):  | 4(20.0):  | 7(35.0): |
| **Type of pathogens** |     |                     |      |           |            |         |           |                 |           |           |           |
| G- alone          | 42  | 8.9(7.0,12.8)      | 79(70.88) | 29.3(13.6,3.9) | 1.6(0.8,4.9) | 14(33.3)| 25(59.5) | 13(31.0) | 18(42.9): | 18(42.9): | 6(14.3): |
| G+ alone          | 26  | 10.7(7.5,15.5)     | 79(74.86) | 34.0(14.4,7.3) | 1.5(0.6,2.8) | 10(38.5)| 16(61.5) | 5(19.2)  | 8(30.8):  | 12(46.2): | 6(23.1): |
| Fungus alone      | 23  | 10.3(5.7,15.1)     | 79(69.88) | 20.4(9.3,5.5) | 1.5(0.9,4.5) | 7(30.4)| 11(47.8) | 4(17.4)  | 7(30.4):  | 10(43.5): | 6(26.1): |
| **Number of strains** |     |                     |      |           |            |         |           |                 |           |           |           |
| One               | 86  | 9.7(6.6,13.0)      | 79(70.87) | 27.6(13.5,5.7) | 1.5(0.9,4.5) | 29(33.7)| 49(57.0)** | 21(24.4)** | 30(34.9): | 39(45.3): | 17(19.8): |
| Two               | 16  | 10.0(6.0,14.8)     | 80(72.88) | 10.9(7.2,7.1) | 1.1(0.5,2.8) | 6(37.5)| 12(75.0) | 9(56.3)  | 5(31.3):  | 8(50.0):  | 3(18.8): |
| Three or more     | 18  | 12.6(6.5,21.8)     | 82(74.88) | 55.2(9.6,9.4) | 1.2(0.5,5.9) | 6(33.3)| 18(100.0) | 17(94.4) | 5(27.8):  | 5(27.8):  | 3(18.8): |
Abbreviations: N: number; WBC: white blood cells; N(%): percentage of neutrophils; CRP: C-reactive protein; PCT: procalcitonin; SIRS: system inflammatory reaction syndrome; ACLF: acute-on-chronic liver failure; SBP: spontaneous bacterial peritonitis; G-: Gram-negative bacteria; G+: Gram-positive bacteria.

aOther infections included urinary tract infection alone (8): skin and soft tissue infection alone (1): infections diarrhea alone (2): spontaneous bacterial empyema alone (1): the undefined infection alone (4).

*P-value<0.05.

**P-value<0.01.

***P-value<0.001.
| Microorganisms                  | Number (n=53) | Constituent ratio(%) | Source of specimens(n=210) |
|--------------------------------|---------------|----------------------|---------------------------|
|                                |               | Ascites | Sputum | Urine | Blood | pleural fluid | Other secretion |
| Gram-positive bacteria(n=53)   |               |         |        |       |       |               |                |
| Enterococcus faecium           | 19            | 9.0     | 9      | 2     | 3     | 2             | 1               | 2               |
| Staphylococcus aureus          | 7             | 3.3     | 2      | 3     | 1     | 1             | 0               | 0               |
| Staphylococcus epidermidis     | 6             | 2.9     | 2      | 0     | 0     | 4             | 0               | 0               |
| Staphylococcus hominis         | 5             | 2.4     | 4      | 0     | 0     | 1             | 0               | 0               |
| Enterococcus faecalis          | 4             | 1.9     | 2      | 0     | 2     | 0             | 0               | 0               |
| Staphylococcus haemolyticus    | 2             | 1.0     | 0      | 1     | 0     | 1             | 0               | 0               |
| Bacillus cereus                | 2             | 1.0     | 0      | 0     | 0     | 2             | 0               | 0               |
| Streptococcus pneumoniae       | 1             | 0.5     | 0      | 0     | 0     | 1             | 0               | 0               |
| Streptococcus oralis           | 1             | 0.5     | 1      | 0     | 0     | 0             | 0               | 0               |
| Bacillus pumilus               | 1             | 0.5     | 0      | 0     | 0     | 1             | 0               | 0               |
| Staphylococcus capitis         | 1             | 0.5     | 1      | 0     | 0     | 0             | 0               | 0               |
| Methic                         | 1             | 0.5     | 1      | 0     | 0     | 0             | 0               | 0               |
|                          |   |   |   |   |   |   |   |
|--------------------------|---|---|---|---|---|---|---|
| Lactobacillus fermenti   | 1 | 0.5 | 1 | 0 | 0 | 0 | 0 |
| Bacillus vegetablis      | 1 | 0.5 | 0 | 0 | 0 | 1 | 0 |
| Staphylococcus lentus    | 1 | 0.5 | 0 | 0 | 0 | 1 | 0 |
| Gram-negative bacteria( n=104) | | | | | | | |
| Escherichia coli         | 39 | 18.6 | 23 | 2 | 1 | 12 | 1 |
| Klebsiella pneumoniae    | 24 | 11.4 | 8 | 6 | 2 | 6 | 1 |
| Acinetobacter baumanii   | 12 | 5.7 | 2 | 7 | 0 | 2 | 1 |
| Pseudomonas aeruginosa   | 8  | 3.8 | 1 | 6 | 0 | 1 | 0 |
| Stenotrophomonas maltophilia | 8 | 3.8 | 0 | 7 | 0 | 0 | 1 |
| Klebsiella oxytoca       | 3  | 1.4 | 0 | 1 | 1 | 1 | 0 |
|                          | Chryseobacterium indologenes | Entero bacter aerogenes | Entero bacter asburiae | Raoult ella ornithinolytica | Entero bacter cloacae | Raoult ella planticola | Burkholderia cepacia | Pseudomonas putida | Flavobacterium meningosepticum | Fungi(n = 53) |
|--------------------------|------------------------------|------------------------|------------------------|----------------------------|-----------------------|------------------------|----------------------|----------------|---------------------------------|----------------|
|                          | 2                            | 1.0                    | 2                      | 0                          | 0                     | 0                      | 0                    | 0              | 0                               | 23             |
| Aspergillus fumigatus    |                              |                        |                        |                            |                       |                        |                      |                 |                                 | 11.0           |
| Candida albicans         | 18                           | 8.6                    | 2                      | 12                         | 4                     | 0                      | 0                    | 0              | 0                               | 8.6            |
| Candida tropicalis       | 4                            | 1.9                    | 1                      | 3                           | 0                     | 0                      | 0                    | 0              | 0                               | 1.9            |
|                  |       |   |   |   |   |   |   |
|------------------|-------|---|---|---|---|---|---|
| **alis**         |       |   |   |   |   |   |   |
| Candida parap siliosis | 2     | 1.0 | 0  | 1  | 1  | 0  | 0  |
| Candida krusei   |       |   |   |   |   |   |   |
| Candida glabrata | 1     | 0.5 | 0  | 1  | 1  | 0  | 0  |
| Aspergillus fla vus | 1     | 0.5 | 0  | 1  | 0  | 0  | 0  |
| Mucor            | 1     | 0.5 | 0  | 1  | 0  | 0  | 0  |
Table 4 Predictors for 28-day mortality by Cox analysis in patients with HBV-ACLF

| Predictors                | Univariate analysis |                      | Multivariate analysis |                      |
|---------------------------|---------------------|----------------------|-----------------------|----------------------|
|                           | HR(95% CI)          | P-value              | HR(95% CI)           | P-value              |
|                           |                     |                      |                       |                      |
| Age (years)               | 1.001(0.986 to 1.015) | 0.934                |                       |                      |
| BMI (kg/m²)               | 1.022(0.989 to 1.056) | 0.201                |                       |                      |
| MAP (mmHg)                | 1.007(0.992 to 1.022) | 0.376                |                       |                      |
| Laboratory data           |                     |                      |                       |                      |
| WBC count (10⁹/L)         | 1.045(1.020 to 1.071) | <0.001               |                       |                      |
| Platelet count (10⁹/L)    | 0.999(0.996 to 1.002) | 0.416                |                       |                      |
| Total bilirubin (μmol/L)  | 1.001(1.000 to 1.002) | 0.072                | 1.001(1.000 to 1.002) | 0.019                |
| Albumin (g/L)             | 0.992(0.964 to 1.022) | 0.599                |                       |                      |
| INR                       | 1.694(1.420 to 2.021) | <0.001               | 1.730(1.472 to 2.035) | <0.001               |
| Creatinine (μmol/L)       | 1.002(1.000 to 1.003) | 0.022                |                       |                      |
| Serum sodium (mmol/L)     | 0.977(0.953 to 1.001) | 0.062                |                       |                      |
| HBV-DNA level (IU/ml)     |                     |                      |                       |                      |
| ≤200                      | 1                   | 0.109                |                       |                      |
| 200-2×10⁴                  | 0.779(0.488 to 1.245) | 0.297                |                       |                      |
| 2×10⁴-2×10⁶               | 1.090(0.705 to 1.685) | 0.699                |                       |                      |
| ≥2×10⁶                    | 1.351(0.867 to 2.107) | 0.184                |                       |                      |
| Complication (%)          |                     |                      |                       |                      |
| Infection                 | 1.725(1.225 to 2.427) | 0.002                | 1.515(1.071 to 2.144) | 0.019                |
| Ascites                   | 0.868(0.502 to 1.501) | 0.612                |                       |                      |
|                | Hazard Ratio | p-Value 1 | Hazard Ratio | p-Value 2 |
|----------------|--------------|-----------|--------------|-----------|
| Acute kidney injury | 1.549 (1.134 to 2.116) | 0.006 | 1.875 (1.365 to 2.577) | <0.001 |
| Haemorrhage | 1.860 (1.205 to 2.871) | 0.005 |
| HE            | 1.472 (1.295 to 1.674) | <0.001 | 1.854 (1.352 to 2.544) | <0.001 |

Abbreviations: HBV-ACLF: hepatitis B virus related acute-on-chronic liver failure; HR: hazard ratio; BMI: body mass index; MAP: mean arterial pressure; WBC: white blood cells; INR: international normalized ratio; HBV-DNA: hepatitis B virus deoxyribonucleic acid; HE: hepatic encephalopathy.
Table 5  Predictors for 28-day mortality by Cox analysis in HBV-ACLF patients with infection

| Predictors                          | Univariate analysis | Multivariate analysis |
|-------------------------------------|---------------------|-----------------------|
|                                     | HR(95% CI)          | P-value               | HR(95% CI)          | P-value               |
|                                     |                     |                       |                     |                       |
| Age(years)                          | 0.996(0.980 to 1.013) | 0.676                 |                       |                       |
| BMI(kg/m²)                          | 1.028(0.979 to 1.078) | 0.268                 |                       |                       |
| MAP(mmHg)                           | 1.001(0.985 to 1.018) | 0.901                 |                       |                       |
| Laboratoy data                      |                     |                       |                     |                       |
| WBC count (10⁹/L)                   | 1.038(1.010 to 1.066) | 0.007                 |                       |                       |
| Platelet count (10⁹/L)              | 0.998(0.995 to 1.002) | 0.306                 |                       |                       |
| Total bilirubin(μmol/L)             | 1.000(0.999 to 1.001) | 0.498                 |                       |                       |
| Albumin(g/L)                        | 0.998(0.967 to 1.030) | 0.913                 |                       |                       |
| INR                                 | 1.755(1.455 to 2.118) | <0.001                | 1.482(1.229 to 1.788) | <0.001                |
| Creatinine(μmol/L)                  | 1.001(1.000 to 1.003) | 0.105                 |                       |                       |
| Serum sodium(mmol/L)                | 0.983(0.955 to 1.011) | 0.233                 |                       |                       |
| HBV-DNA level (IU/ml)               |                     |                       |                     |                       |
| ≤200                                | 1                   | 0.126                 |                       |                       |
| 200-2×10⁴                           | 0.599(0.341 to 1.051) | 0.074                 |                       |                       |
| 2×10⁴-2×10⁶                         | 0.864(0.528 to 1.415) | 0.562                 |                       |                       |
| ≥2×10⁶                              | 1.151(0.694 to 1.911) | 0.586                 |                       |                       |
| SIRS                                | 1.658(1.136 to 2.421) | 0.009                 |                       |                       |
| Type of infection(%)                |                     |                       |                     |                       |
| Pneumonia                           | 2.315(1.563 to 3.429) | <0.001                | 1.904(1.268 to 2.860) | 0.002                 |
| SBP                                 | 0.623(0.429)         | 0.013                 |                       |                       |
| Number of infection sites | Bacteremia | HR (95% CI) | p-value |
|---------------------------|------------|-------------|---------|
| One                       | 1.260 (0.815 to 1.949) | 0.299       |
| Two                       | 1.184 (0.778 to 1.803) | 0.430       |
| Three or more             | 1.718 (1.008 to 2.926) | 0.046       |

| Number of isolated microorganisms | HR (95% CI) | p-value |
|-----------------------------------|-------------|---------|
| Zero                              | 1.000       | 0.638   |
| One                               | 0.941 (0.625 to 1.418) | 0.773   |
| Two                               | 0.911 (0.456 to 1.819) | 0.791   |
| Three or more                     | 1.375 (0.749 to 2.524) | 0.304   |

| Complication | HR (95% CI) | p-value |
|--------------|-------------|---------|
| Ascites      | 0.777 (0.585 to 1.031) | 0.081   |
| Hemorrhage   | 1.447 (0.885 to 2.367) | 0.141   |
| Acute kidney injury | 1.456 (1.001 to 2.117) | 0.049   | 1.529 (1.046 to 2.235) | 0.028   |
| HE           | 1.409 (1.214 to 1.636) | <0.001  | 1.263 (1.087 to 1.466) | 0.002   |
| Sepsis (%)   | 2.740 (1.756 to 4.273) | <0.001  | 2.166 (1.372 to 3.421) | 0.001   |
| Sepsis shock (%) | 2.322 (1.612 to 3.345) | <0.001  |

Abbreviations: HBV-ACLF: hepatitis B virus related acute-on-chronic liver failure; HR: hazard ratio; BMI: body mass index; MAP: mean arterial pressure; WBC: white blood cells; INR: international normalized ratio; HBV-DNA: hepatitis B virus deoxyribonucleic acid; SIRS: system inflammatory reaction syndrome; SBP: spontaneous bacterial peritonitis; HE: hepatic encephalopathy.

**Figures**
Figure 1

Flow chart of the patients with HBV-ACLF included and excluded from the study. HBV-ACLF: hepatitis B virus related acute-on-chronic liver failure.

56 patients were excluded for the following reasons:
- 2 less than 18 years old
- 22 had hepatocellular carcinoma or other malignant tumors
- 4 with serious extra-hepatic diseases
- 7 received liver transplantation within 28 days
- 14 lost to follow-up within 28 days
- 7 with a hospital stay less than 48 hours
Figure 2

(A) Kaplan-Meier survival curves of patients with and without infection. (B) Kaplan-Meier survival curves of patients with different ACLF grades with and without infection. (C) The 28-day mortality rate of patients with different ACLF grades with and without infection.